Navitoclax

Scientific Overview: Pan-BCL-2 family inhibitor; thrombocytopenia from BCL-XL; combined with ruxolitinib for MF. BCL-2 + BCL-XL — thrombocytopenia limits monotherapy but drives combos

Mechanism of Action: BCL-2/BCL-XL/BCL-W Inhibitor

Purity: ≥99%  |  Molecular Formula: C47H55ClN6O6S

For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.